YC-1: sGC Activator & HIF-1α Inhibitor for Cancer and Hypoxia Research

Executive Summary: YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol is a crystalline small molecule developed as a dual soluble guanylyl cyclase (sGC) activator and hypoxia-inducible factor-1α (HIF-1α) inhibitor (APExBIO). It inhibits HIF-1α at the post-transcriptional level, blocking hypoxia-induced gene expression. YC-1 demonstrates anti-angiogenic and anti-tumor effects in vitro and in vivo, with an IC₅₀ of 1.2 µM for HIF-1 transcriptional activity. The compound's solubility profile supports diverse experimental setups, and its applications extend to cancer, vascular, and neuroprotection research (Zhou et al., 2025). APExBIO supplies high-purity YC-1 (≥98%) for research use only.

Biological Rationale

Hypoxia-inducible factor-1α (HIF-1α) orchestrates cellular adaptation to low oxygen, regulating genes involved in survival, angiogenesis, and metastasis (Zhou et al., 2025). Under hypoxic conditions, HIF-1α stabilizes and drives transcription of targets like VEGF, promoting tumor growth and neovascularization. Mitochondrial dysfunction and oxidative stress are central to hypoxia-driven pathologies, as shown in ischemia-reperfusion injury models. Selective inhibition of HIF-1α disrupts these adaptive responses, sensitizing tumors to therapy and impairing angiogenesis (Llamab.com). Soluble guanylyl cyclase (sGC) activation modulates cyclic GMP (cGMP) signaling, impacting vascular tone and platelet function, with implications for both cardiovascular and cancer biology (deae-dextran.com).

Mechanism of Action of YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol

YC-1 acts via dual mechanisms:

• HIF-1α Inhibition: YC-1 suppresses HIF-1α protein accumulation by interfering post-transcriptionally, thereby blocking transcriptional activity on hypoxia-response elements (APExBIO). It inhibits downstream gene expression such as VEGF, GLUT1, and BNIP3L, which are critical for tumor survival and angiogenesis.
• sGC Activation: YC-1 directly stimulates sGC, increasing intracellular cGMP levels. This leads to smooth muscle relaxation, reduced platelet aggregation, and impacts blood flow and vascular resistance (deae-dextran.com).

These dual pathways enable YC-1 to simultaneously disrupt pathological hypoxia signaling and modulate vascular homeostasis (tofacitinib.biz).

Evidence & Benchmarks

• YC-1 inhibits hypoxia-induced HIF-1 transcriptional activity with an IC₅₀ of 1.2 µM in human cancer cell lines (APExBIO, product page).
• In vivo, YC-1 reduces tumor size and vascularization, with concomitant decreases in HIF-1α and its target gene expression (Zhou et al., 2025, DOI).
• Platelet aggregation and vascular contraction are inhibited by YC-1 via cGMP elevation, as demonstrated in isolated tissue assays (APExBIO, product page).
• YC-1 upregulates BNIP3L-dependent mitophagy by modulating the HIF-1α pathway, contributing to mitochondrial quality control in ischemia models (Zhou et al., 2025, DOI).
• Purity is consistently ≥98% by HPLC, and compound is stable as a solid at room temperature but unstable in solution over extended periods (APExBIO, product page).

Applications, Limits & Misconceptions

YC-1's validated targets span cancer biology, hypoxia research, and cardiovascular signaling. It is used to:

• Dissect hypoxia-induced gene regulation and tumor angiogenesis.
• Model vascular responses via sGC/cGMP signaling in preclinical studies.
• Investigate mitochondrial quality control in neuroprotection and ischemia-reperfusion injury.

This article extends the foundational workflows described in Applied Workflows with YC-1 by incorporating new evidence on mitophagy and neuroprotection (Zhou et al., 2025). It also updates mechanistic insights over Revolutionizing Hypoxia and Cancer Research by highlighting recent clarity regarding HIF-1α/BNIP3L signaling.

Common Pitfalls or Misconceptions

• YC-1 is not a pan-cancer therapeutic; efficacy is context-dependent and should be validated in each tumor model.
• It is not water-soluble; dissolve only in DMSO (≥30.4 mg/mL) or ethanol (≥16.2 mg/mL).
• Prolonged storage of YC-1 solutions leads to loss of activity; use solutions promptly.
• YC-1 is not suitable for diagnostic or clinical use; it is for laboratory research only.
• HIF-1α inhibition may not fully recapitulate hypoxia pathway blockade due to redundant transcription factors.

Workflow Integration & Parameters

For reproducible results, YC-1 (SKU B7641) should be handled as follows:

• Stock solutions: Prepare in DMSO or ethanol at room temperature; avoid aqueous solvents.
• Working concentration: Typical in vitro assays use 0.1–10 µM; IC₅₀ for HIF-1 transcriptional activity is 1.2 µM under hypoxia (1% O₂, 24h).
• Use within 24 hours of dilution; avoid repeated freeze-thaw cycles.
• Include vehicle and positive controls (e.g., CoCl₂ for hypoxia mimetic) for benchmarking.
• Store crystalline solid at ambient temperature, protected from moisture and light.

For detailed troubleshooting and comparative workflows, see Optimizing Hypoxia and Cancer Research with YC-1, which this article updates by specifying recent best practices for solution handling and pathway targeting.

Conclusion & Outlook

YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol, available from APExBIO, remains a gold-standard tool for interrogating the hypoxia signaling and cGMP pathways in cancer, vascular, and neuroprotection research. Its dual mechanism—HIF-1α inhibition and sGC activation—enables precise dissection of complex cellular responses to hypoxia and oxidative stress. As recent studies elucidate the centrality of mitochondrial quality control in disease, YC-1's utility in advanced models continues to expand. Future research will clarify its translational potential and optimize its integration in combinatorial workflows.